September 10, 2019
Unibio completes US$15 million financing round
Danish biotech company Unibio International plc has raised US$15 million from existing and new shareholders, the company announced in late August.
The investment will allow Unibio to initiate full-scale production projects, together with local partners, around the world (including in the United States and the Persian Gulf).
In addition, Unibio will expand its R&D activities and strengthen the organisation for the commercial stage but will first begin a global roll-out of additional commercial projects around the world. The financing was led by West Hill Capital. Unibio is still in discussion with potential additional corporate and financial investors.
"We are very pleased with the continued backing of our shareholders, and very pleased to welcome new shareholders to Unibio," said Unibio Group CEO Henrik Busch-Larsen.
"We have made strong progress in the past few years, with continued productivity improvements in our technology and hence increased cost-effectiveness. We have also signed two licence agreements. I would like to thank our shareholders for their support, our people for their constant dedication and West Hill for their great efforts on Unibio's behalf. Together, we are addressing one of the biggest challenges of our time, how to feed [a global population of] soon to be 10 billion people, without placing even more stress on our planet."
Unibio's fermentation technology allows the large-scale production of affordable, high-quality protein, sold under the brand name Uniprotein®, via a process that uses little water and no agricultural land. Protein for animal consumption can thus be produced without the use of farmland or fishing, leading to a more sustainable food production.
The company's Uniprotein® is an organic, safe and extensively tested microbial protein that has been approved by the European Union for all animal and fish species.